国: 欧州連合
言語: 英語
ソース: EMA (European Medicines Agency)
teriparatide
Sun Pharmaceutical Industries Europe B.V.
H05AA02
teriparatide
Calcium homeostasis
Osteoporosis; Osteoporosis, Postmenopausal
Teriparatide SUN is indicated in adults.Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5.1). In postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated.Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.1).
Revision: 1
Authorised
2022-11-18
20 B. PACKAGE LEAFLET 21 PACKAGE LEAFLET: INFORMATION FOR THE USER TERIPARATIDE SUN 20 MICROGRAMS/80 MICROLITERS SOLUTION FOR INJECTION IN PRE-FILLED PEN teriparatide READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Teriparatide SUN is and what it is used for 2. What you need to know before you use Teriparatide SUN 3. How to use Teriparatide SUN 4. Possible side effects 5. How to store Teriparatide SUN 6. Content of the pack and other information 1. WHAT TERIPARATIDE SUN IS AND WHAT IT IS USED FOR Teriparatide SUN contains the active substance teriparatide that is used to make the bones stronger, and to reduce the risk of fractures by stimulating bone formation. Teriparatide SUN is used to treat osteoporosis in adults. Osteoporosis is a disease that causes your bones to become thin and fragile. This disease is especially common in women after the menopause, but it can also occur in men. Osteoporosis is also common in patients receiving corticosteroids. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE TERIPARATIDE SUN DO NOT USE TERIPARATIDE SUN - if you are allergic to teriparatide or any of the other ingredients of this medicine (listed in section 6) - if you suffer from high calcium levels (pre-existing hypercalcaemia) - if you suffer from serious kidney problems - if you have ever been diagnosed with bone cancer or other cancers that have spread (metastasised) to your bones - if you have certain bone diseases. If you have a bone disease, tell your doctor - if you have unexplained high levels of alkaline 完全なドキュメントを読む
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Teriparatide SUN 20 micrograms/80 microliters solution for injection in pre-filled pen 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 80 microliters contains 20 micrograms of teriparatide. Each pre-filled pen of 2.4 ml contains 600 micrograms of teriparatide (corresponding to 250 micrograms per ml). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection Clear, colourless solution free from visible particles. The pH is between 3.8 and 4.5. The osmolality is between 250 to 350 mOsmol. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Teriparatide SUN is indicated in adults. Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5.1). In postmenopausal women, a significant reduction in the incidence of vertebral and non- vertebral fractures but not hip fractures has been demonstrated. Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.1). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The recommended dose of teriparatide is 20 micrograms administered once daily. The maximum total duration of treatment with teriparatide should be 24 months (see section 4.4). The 24-month course of teriparatide should not be repeated over a patient’s lifetime. Patients should receive supplemental calcium and vitamin D supplements if dietary intake is inadequate. Following cessation of teriparatide therapy, patients may be continued on other osteoporosis therapies. Special populations _ _ _Elderly patients _ Dose adjustment based on age is not required (see section 5.2). 3 _Renal impairment _ Teriparatide must not be used in patients with severe renal impairment (see section 4.3). In patients with moderate renal impairment, teriparatide should be used with caution. No special caution is required for patients with mild renal impairment. _Hepatic impairment _ 完全なドキュメントを読む